Financials
Financial year 2025
CMAX BIOTECH CONSULTING from Hasselt, company number BE0784922317, closed financial year 2025 with a result of € -12,278 after tax. For that financial year CMAX BIOTECH CONSULTING recorded a gross margin of € -8,063 and equity of € 5,646. Compared with financial year 2024, the result moved from € 74,864 to € -12,278. The company made a loss. The buffer shrank hard: equity is 93 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 5,646
▼ 93% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12,278
▼ still € 74,864 profit in 2024
Profit after tax over the fiscal year.
€ 48,551
▼ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1,646.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 2,189
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 28
▼ € 9,652 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 7,681
▼ 21% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 44,849 | € 85,823 | € 98,079 | € -8,063 | ▼ € 106,142 |
| Profit after taxes | € 33,212 | € 65,349 | € 74,864 | € -12,278 | ▼ € 87,142 |
| Equity | € 37,212 | € 102,560 | € 77,424 | € 5,646 | ▼ 93% |
| Total debts | € 23,289 | € 32,715 | € 129,348 | € 46,432 | ▼ 64% |
| Cash | € 27,536 | € 78,404 | € 167,671 | € 48,551 | ▼ 71% |
| Retained profit | € 33,212 | € 98,560 | € 73,424 | € 1,646 | ▼ 98% |
| Dividend | € 0 | € 0 | € 100,000 | € 59,500 | ▼ 40% |
| Balance sheet total | € 60,500 | € 135,276 | € 206,772 | € 52,078 | ▼ 75% |
Key figures of CMAX BIOTECH CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CMAX BIOTECH CONSULTING?
What happened at CMAX BIOTECH CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 12,278 (▼ € 87,142 vs 2024). Source: NBB ↗
- New establishment in Hasselt. KBO
- Kateryna RUBAN became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 33,212 profit in 2022 to € 12,278 loss in 2025.
Paid € 47,481 in corporate taxes since 2022.
Best year ever: 2024, with € 74,864 profit.
Paid out € 159,500 in dividends to the owners in total.
Management
Behind CMAX BIOTECH CONSULTING is Kateryna RUBAN.
Directors
According to the 2025 annual accounts
Kateryna RUBAN
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Bremstraat 24
3511 Hasselt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0784.922.317
- VAT number
- BE 0784.922.317
- Registered office
- Bremstraat 24, 3511 Hasselt
- Names & denominations
- CMAX BIOTECH CONSULTING
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 April 2022
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten